TY - JOUR
T1 - Continuous positive airway pressure increases pulsatile growth hormone secretion and circulating insulin-like growth factor-1 in a time-dependent manner in men with obstructive sleep apnea
T2 - A randomized sham-controlled study
AU - Hoyos, Camilla M.
AU - Killick, Roo
AU - Keenan, Daniel M.
AU - Baxter, Robert C.
AU - Veldhuis, Johannes D.
AU - Liu, Peter Y.
PY - 2014/4/1
Y1 - 2014/4/1
N2 - Study Objectives: To assess the time-dependent effect of continuous positive airway pressure (CPAP), on insulin-like growth factor-1 (IGF-1), IGF binding proteins (IGFBPs) and pulsatile growth hormone (GH) secretion. Design: A randomized, double-blind, sham-controlled, parallel group study. Participants: Sixty-five middle-aged men with moderate to severe obstructive sleep apnea. Intervention: Active (n = 34) or sham (n = 31) CPAP for 12 weeks, followed by 12 weeks of active CPAP (n = 65). Measurements and Results: Fasting morning IGF-1, IGFBP-3, and IGFBP-1 blood levels at 0, 6, 12, and 24 weeks. Overnight GH secretion was calculated by mathematical deconvolution of serial GH measurements from serum samples collected every 10 min (22: 00-06: 00) during simultaneous polysomnography in a subset of 18 men (active n = 11, sham n = 7) at week 12. Active, compared with sham, CPAP increased IGF-1 at 12 weeks (P = 0.006), but not at 6 weeks (P = 0.44). Changes in IGFBP-3 and IGFBP-1 were not different between groups at 6 or 12 weeks (all P ≥ 0.15). At week 24, there was a further increase in IGF-1 and a decrease in IGFBP-1 in the pooled group (P = 0.0001 and 0.046, respectively). In the subset, total (P = 0.001) and pulsatile (P = 0.002) GH secretion, mean GH concentration (P = 0.002), mass of GH secreted per pulse (P = 0.01) and pulse frequency (P = 0.04) were all higher after 12 weeks of CPAP compared with sham. Basal secretion, interpulse regularity, and GH regularity were not different between groups (all P > 0.11). Conclusions: Twelve weeks, but not 6 weeks, of CPAP increases IGF-1, with a further increase after 24 weeks. Total and pulsatile GH secretion, secretory burst mass and pulse frequency are also increased by 12 weeks. CPAP improves specific elements of the GH/IGF-1 axis in a time-dependent manner. Clinical Trials Registration: Australia New Zealand Clinical Trials Network, www.anzctr.org.au, number ACTRN12608000301369.
AB - Study Objectives: To assess the time-dependent effect of continuous positive airway pressure (CPAP), on insulin-like growth factor-1 (IGF-1), IGF binding proteins (IGFBPs) and pulsatile growth hormone (GH) secretion. Design: A randomized, double-blind, sham-controlled, parallel group study. Participants: Sixty-five middle-aged men with moderate to severe obstructive sleep apnea. Intervention: Active (n = 34) or sham (n = 31) CPAP for 12 weeks, followed by 12 weeks of active CPAP (n = 65). Measurements and Results: Fasting morning IGF-1, IGFBP-3, and IGFBP-1 blood levels at 0, 6, 12, and 24 weeks. Overnight GH secretion was calculated by mathematical deconvolution of serial GH measurements from serum samples collected every 10 min (22: 00-06: 00) during simultaneous polysomnography in a subset of 18 men (active n = 11, sham n = 7) at week 12. Active, compared with sham, CPAP increased IGF-1 at 12 weeks (P = 0.006), but not at 6 weeks (P = 0.44). Changes in IGFBP-3 and IGFBP-1 were not different between groups at 6 or 12 weeks (all P ≥ 0.15). At week 24, there was a further increase in IGF-1 and a decrease in IGFBP-1 in the pooled group (P = 0.0001 and 0.046, respectively). In the subset, total (P = 0.001) and pulsatile (P = 0.002) GH secretion, mean GH concentration (P = 0.002), mass of GH secreted per pulse (P = 0.01) and pulse frequency (P = 0.04) were all higher after 12 weeks of CPAP compared with sham. Basal secretion, interpulse regularity, and GH regularity were not different between groups (all P > 0.11). Conclusions: Twelve weeks, but not 6 weeks, of CPAP increases IGF-1, with a further increase after 24 weeks. Total and pulsatile GH secretion, secretory burst mass and pulse frequency are also increased by 12 weeks. CPAP improves specific elements of the GH/IGF-1 axis in a time-dependent manner. Clinical Trials Registration: Australia New Zealand Clinical Trials Network, www.anzctr.org.au, number ACTRN12608000301369.
KW - Continuous positive airway pressure
KW - Growth hormone
KW - IGF binding protein
KW - Insulin-like growth factor 1
KW - Obstructive sleep apnea
KW - Pulsatility
UR - http://www.scopus.com/inward/record.url?scp=84897402649&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84897402649&partnerID=8YFLogxK
U2 - 10.5665/sleep.3580
DO - 10.5665/sleep.3580
M3 - Article
C2 - 24899762
AN - SCOPUS:84897402649
SN - 0161-8105
VL - 37
SP - 733
EP - 741
JO - Sleep
JF - Sleep
IS - 4
ER -